Home/Investors/OrbiMed Asia

OrbiMed Asia

Biotech Investor · 12 portfolio companies

Portfolio

12

Focus Areas

9

Top Stage

phase-1

Investment Focus

Metabolic Oncology Gene Therapy Cell Therapy Infectious Disease Immunology Neuroscience Genetics & Genomics Antibodies

Portfolio Companies

Company	Stage	Valuation	Focus
Evive Biotech	phase-2	—	Metabolic
Conjustar	phase-1	—	Oncology
Biomics Biopharma	preclinical	—	Oncology, Gene Therapy
Hepagene Therapeutics	phase-2	—	Infectious Disease, Metabolic
Immunotech Biopharm	phase-1	—	Oncology, Immunology
Kanglin Biotechnology	phase-1	—	Oncology, Immunology
Doer Biologics	phase-1	—	Oncology, Immunology
TCRCure	phase-1	—	Oncology, Infectious Disease
Lupeng Pharmaceutical	phase-2	—	Neuroscience
Biokey	commercial	—	Infectious Disease, Genetics & Genomics
C-Ray Therapeutics	phase-1	—	Oncology, Antibodies
BriSTAR Immunotech	phase-1	—	Oncology, Immunology

Frequent Co-Investors

Lilly Asia Ventures6 shared TF Capital5 shared Sinovation Ventures5 shared CBC Group4 shared GL Ventures2 shared Legend Capital1 shared Sequoia Capital China1 shared